Product Description
BRG01 is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer (NPC) treatment. (Sourced from: https://www.biosyngen.com/index.php?m=home&c=Lists&a=index&tid=10)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Nasopharyngeal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20230761 | P1 |
Not yet recruiting |
Nasopharyngeal Cancer |
None |